Pharmaceuticals News and Research

RSS

Cellectis, Medicago complete first step in therapeutic protein research collaboration

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and Cellectis plant sciences, a US-based subsidiary of Cellectis Group, the specialist in genome engineering, today announced the successful completion of the first step in their research collaboration to improve therapeutic proteins produced in tobacco plants.

4 Oct 2012

Two court cases could affect medicines patent law in India

In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."

3 Oct 2012

Financial Times examines legal disputes in India over pharmaceutical patent laws

The Financial Times reports on a legal dispute between the Indian government and the German pharmaceutical group Bayer, writing, "Bayer is appealing against the Indian patent controller's decision in March to override the company's monopoly on its cancer drug Nexavar, and to allow an Indian company to produce and sell the life-extending drug for just $173 a month -- one-sixth of the $5,500 a month price charged by Bayer."

3 Oct 2012

Ranibizumab injections keep those with AMD driving longer

The advanced neovascular, or “wet,” form of age-related macular degeneration (AMD), left untreated, is the most common cause of vision loss among the elderly and a leading reason for their loss of driving privileges. But results of a new study, published in the online version of the journal Ophthalmology, suggest that monthly injections of ranibizumab improve eye chart test results required for a driver’s license, build driver confidence and keep those with AMD driving longer.

3 Oct 2012

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

3 Oct 2012

Biologists combine laser cutting technology with modern sequencing to analyze gene activity in fungi

With a combination of microscopic laser scissors and modern sequencing methods, biologists at the Ruhr-Universit-t have analyzed the activity of genes in the entire genome of certain fungi in one fell swoop.

3 Oct 2012

New positively-charged nanoparticles can be useful MRI agents to monitor transplanted islet cells

In a study to investigate the detection by MRI of six kinds of positively-charged magnetic iron oxide nanoparticles designed to help monitor transplanted islet cells, a team of Japanese researchers found that the charged nanoparticles they developed transduced into cells and could be visualized by MRI while three kinds of commercially available nanoparticles used for controls could not.

3 Oct 2012

Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced commencement of a Phase 2 study of a d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no approved amphetamine-based transdermal treatment option available for ADHD.

3 Oct 2012

Alimera completes $40 million convertible preferred stock sale

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has completed the sale of $40 million of Series A Convertible Preferred Stock and warrants to purchase Series A Preferred to a group of institutional investors, including both existing and new investors, in a private placement.

3 Oct 2012

Biomarkers can increase success rate of clinical trials for breast cancer drugs by almost 50%

Using biological markers--genetic characteristics that are associated with some patients with breast cancer--can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research from the University of Toronto Mississauga.

3 Oct 2012

VOA News reports on Syria's health crisis in midst of civil war

"The United Nations estimates the civil war raging in Syria has left more than 2.5 million people in dire need of food, water, drugs and medical supplies," VOA News reports.

2 Oct 2012

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA.

2 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Common RNA pathway links frontotemporal lobar dementia with ALS

Two proteins previously found to contribute to ALS, also known as Lou Gehrig's disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.

1 Oct 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

Report: State, federal governments collected $30B in fraud settlements in 20 years

A new report finds federal and state authorities have collected more than $30 billion from drug company fraud settlements in the last 20 years.

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

EvaluatePharma’s new service focuses on medical device and diagnostic sector

EvaluatePharma, the premier source for life science sector analysis and consensus forecasts, today announced the launch of EvaluateMedTech, a new intelligence service focused on the medical device and diagnostic sector.

29 Sep 2012

Pharmaceuticals News and Research

Cellectis, Medicago complete first step in therapeutic protein research collaboration

Two court cases could affect medicines patent law in India

Financial Times examines legal disputes in India over pharmaceutical patent laws

Ranibizumab injections keep those with AMD driving longer

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Biologists combine laser cutting technology with modern sequencing to analyze gene activity in fungi

New positively-charged nanoparticles can be useful MRI agents to monitor transplanted islet cells

Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Alimera completes $40 million convertible preferred stock sale

Biomarkers can increase success rate of clinical trials for breast cancer drugs by almost 50%

VOA News reports on Syria's health crisis in midst of civil war

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Common RNA pathway links frontotemporal lobar dementia with ALS

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

Synta announces results from ganetespib Phase 2b trial on NSCLC

Report: State, federal governments collected $30B in fraud settlements in 20 years

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

EvaluatePharma’s new service focuses on medical device and diagnostic sector

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence